Abstract
Background
The prevalence of osteoporosis is reported differently. We designed this systematic review and meta-analysis to estimate pooled prevalence of osteoporosis and osteopenia in patients with MS.
Methods
Independently, two researchers searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature (conference abstracts and references of the references) up to March 2021. We collected data regarding first author, country of origin, number of enrolled patients, number cases with osteoporosis/ osteopenia, mean age, F/M ratio, mean EDSS, and mean duration of the disease.
Results
Literature search revealed 847 articles and 658 remained after deleting duplicates. Finally, 29 original articles and 6 conference papers remained for meta-analysis. A total of 13,906 patients were evaluated. The pooled prevalence of osteoporosis was 17% (95% CI: 14–20%) (I2 = 90.4%, p < 0.001). The pooled prevalence of osteopenia was 43% (95% CI: 35–51%) (I2 = 97.9%, p < 0.001).
Conclusion
Osteoporosis/osteopenia should be considered in patients with MS.
Similar content being viewed by others
References
Askari, F., et al. 2014, Anxiety in patients with multiple sclerosis: association with disability, depression, disease type and sex. Acta Medica Iranica, 889–892.
Moen SM et al (2012) Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One 7(9):e45703
Moen S et al (2011) Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. Neurology 77(2):151–157
Gibson J, Summers G (2011) Bone health in multiple sclerosis. Osteoporos Int 22(12):2935–2949
Zikan, V., Bone health in patients with multiple sclerosis. Journal of osteoporosis, 2011. 2011.
Moghaddasi M, Aghaei M (2013) Assessment of bone densitometry in Iranian patients with multiple sclerosis: a case-control study. Iran J Neurol 12(1):9
Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281
Kępczyńska K et al (2016) Bone metabolism and vitamin D status in patients with multiple sclerosis. Neurol Neurochir Pol 50(4):251–257
Modesti PA et al (2016) Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PloS one 11(1):e0147601
Marrie RA et al (2009) A cross-sectional study of bone health in multiple sclerosis. Neurology 73(17):1394–1398
Niedziela, N., et al., Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D3. BioMed research international, 2018. 2018.
Le, M.V., et al. Body composition and relation to age in patients with multiple sclerosis. in MULTIPLE SCLEROSIS JOURNAL. 2019. SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND.
Murphy O et al (2016) Bone health in patients with multiple sclerosis relapses. Mult Scler Relat Disord 6:75–80
Zikan, V., et al., Bone mineral density and body composition in men with multiple sclerosis chronically treated with low-dose glucocorticoids. Physiological research, 2012. 61(4).
Haggiag, S., et al., Bone mineral density assessment in a multiple sclerosis population (P06. 163). 2012, AAN Enterprises.
Simonsen CS et al (2016) Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease-a case control study. BMC Neurol 16(1):1–8
Terzi T et al (2010) Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci 17(10):1260–1264
Batista, S., et al. Cognitive impairment is associated with low bone mineral density in multiple sclerosis. in NEUROLOGY. 2011. LIPPINCOTT WILLIAMS & WILKINS 530 WALNUT ST, PHILADELPHIA, PA 19106–3621 USA.
Hammond, N., et al. Comparison of bone effects with Copaxone (R) and interferon-beta in multiple sclerosis. in MULTIPLE SCLEROSIS. 2009. SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND.
El-Ghoneimy AT et al (2009) Contribution of vitamin D to the pathogenesis of multiple sclerosis and its effect on bone. Egypt J Neurol Psychiatry Neurosurg 46:209–222
Lo, L.M.P., et al. 2020, Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis. Journal of Neurology, 1–13.
Dovio A et al (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89(10):4923–4928
Tyblova M et al (2015) Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. Eur J Neurol 22(4):624–632
Kirbas A et al (2013) Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiple sclerosis. Acta Neurol Belg 113(1):43–47
Karahan, S.Z., et al., Lack of association between pulse steroid therapy and bone mineral density in patients with multiple sclerosis. Multiple Sclerosis International, 2016. 2016.
Triantafyllou N et al (2012) Lack of association between vitamin D levels and bone mineral density in patients with multiple sclerosis. J Neurol Sci 313(1–2):137–141
Zorzon M et al (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12(7):550–556
Stepan JJ et al (2004) Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta 348(1–2):147–154
Bisson EJ et al (2019) Multiple sclerosis is associated with low bone mineral density and osteoporosis. Neurol Clin Pract 9(5):391–399
Slouma M et al (2013) THU0383 osteoporosis in epilepsy and multiple sclerosis patients. Ann Rheum Dis 72(Suppl 3):A295–A295
Faulkner M et al (2005) Osteoporosis in long-term care residents with multiple sclerosis. Consult Pharm 20(2):128–136
Smeltzer SC, Zimmerman V, Capriotti T (2005) Osteoporosis risk and low bone mineral density in women with physical disabilities. Arch Phys Med Rehabil 86(3):582–586
Murphy O et al (2013) Patients with an acute multiple sclerosis relapse: a high risk group for osteopenia and osteoporosis. J Neurol Neurosurg Psychiatry 84(11):e2–e2
Kampman, M., et al. Persons with MS are at increased risk of osteopenia and osteoporosis. A ten-year longitudinal study. in MULTIPLE SCLEROSIS JOURNAL. 2018. SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND.
Coskun Benlidayi I et al (2015) Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis. Acta Clin Belg 70(3):188–192
Boz, C. and S.Z. Karahan. Risk factors of reduced bone mass in patients with multiple sclerosis. in MULTIPLE SCLEROSIS JOURNAL. 2012. SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND.
Weinstock-Guttman B et al (2004) Risk of bone loss in men with multiple sclerosis. Mult Scler J 10(2):170–175
Olsson A et al (2015) Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. Mult Scler J 21(12):1557–1565
Varoglu AO et al (2010) The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients. J Back Musculoskelet Rehabil 23(1):25–29
Lambrinoudaki I et al (2013) Vitamin D receptor Bsm1 polymorphism, calcium metabolism and bone mineral density in patients with multiple sclerosis: a pilot study. Neurol Sci 34(8):1433–1439
Bazelier MT et al (2011) The risk of fracture in patients with multiple sclerosis: the UK general practice research. J Bone Miner Res 26(9):2271–2279
Dennison EM et al (2012) Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50(6):1288–1293
prevention, R.f.t. and t.o.g.i.o. update., American College of Rheumatology Ad Hoc Committee on Glucocorticoid‐Induced Osteoporosis. Arthritis Rheum, 2001 44(7) 1496–1503.
Canalis E et al (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319–1328
Hayashi K et al (2009) Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int 20(11):1889–1894
Sioka C et al (2011) Bone mineral density in ambulatory patients with multiple sclerosis. Neurol Sci 32(5):819–824
Ghajarzadeh M et al (2019) The effect of vitamin D supplements on clinical and Para-clinical outcomes in patients with multiple sclerosis: protocol for a systematic review. JMIR Res Protoc 8(4):e12045
Ascherio A (2013) Environmental factors in multiple sclerosis. Expert Rev Neurother 13(sup2):3–9
Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3(Supplement 3):S131–S139
Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7(4):292–304
Kanis JA et al (2009) Assessment of fracture risk. Eur J Radiol 71(3):392–397
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None.
Ethical approval
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Azadvari, M., Mirmosayyeb, O., Hosseini, M. et al. The prevalence of osteoporosis/osteopenia in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurol Sci 43, 3879–3892 (2022). https://doi.org/10.1007/s10072-022-05871-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-022-05871-w